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nasa technology
It was an unlikely moment for inspiration. Engineers David Wolf and Ray Schwarz stopped by their lab around midday. Wolf, of Johnson Space Center, and 
Schwarz, with NASA contractor Krug Life Sciences (now 
Wyle Laboratories Inc.), were part of a team tasked with 
developing a unique technology with the potential to 
enhance medical research. But that wasn’t the focus at the 
moment: The pair was rounding up colleagues interested 
in grabbing some lunch. 
One of the lab’s other Krug engineers, Tinh Trinh, 
was doing something that made Wolf forget about food. 
Trinh was toying with an electric drill. He had stuck the 
barrel of a syringe on the bit; it spun with a high-pitched 
whirr when he squeezed the drill’s trigger. 
At the time, a multidisciplinary team of engineers 
and biologists—including Wolf, Schwarz, Trinh, and 
project manager Charles D. Anderson, who formerly led 
the recovery of the Apollo capsules after splashdown and 
now worked for Krug—was pursuing the development of 
a technology called a bioreactor, a cylindrical device used 
to culture human cells. The team’s immediate goal was 
to grow human kidney cells to produce erythropoietin, 
a hormone that regulates red blood cell production and 
can be used to treat anemia. But there was a major barrier 
to the technology’s success: Moving the liquid growth 
media to keep it from stagnating resulted in turbulent 
conditions that damaged the delicate cells, causing them 
to quickly die. 
The team was looking forward to testing the biore-
actor in space, hoping the device would perform more 
effectively in microgravity. But on January 28, 1986, the 
Space Shuttle Challenger broke apart shortly after launch, 
killing its seven crewmembers. The subsequent grounding 
of the shuttle fleet had left researchers with no access to 
space, and thus no way to study the effects of micrograv-
ity on human cells. 
As Wolf looked from Trinh’s syringe-capped drill to 
where the bioreactor sat on a workbench, he suddenly saw 
a possible solution to both problems.
“It dawned on me that rotating the wall of the reac-
tor would solve one of our fundamental fluid mechanical 
problems, specifically by removing the velocity gradient of 
the tissue culture fluid media near the reactor’s walls,” says 
Wolf. “It looked as though it would allow us to suspend 
the growing cells within the reactor without introducing 
turbulent fluid mechanical conditions.” 
The three engineers skipped lunch. They quickly built 
a prototype from components lying around the lab and 
tested the bioreactor that night using hamster kidney cells 
(cheaper than their human counterparts). When the team 
returned in the morning, not much had changed; the cells 
were all dead. But after running chemical analyses, Wolf 
and his colleagues realized the cells had died from an alto-
gether different reason than before: They had run out of 
nutrients because they grew too fast. The new bioreactor 
was, in a sense, too effective. 
The bioreactor’s rotating wall eliminated the prob-
lematic mechanical forces that had damaged previous 
cell cultures, creating a constant free fall effect within 
the media and suspending the cells in a way very similar 
to microgravity. As the team discovered means of sup-
plying nutrients and oxygen and removing waste at high 
enough rates to support the cell cultures, they noticed 
new structures forming within the bioreactor. While 
standard human cell cultures grown in Petri dishes settle 
into flat layers thanks to gravity, the NASA bioreactor’s 
microgravity mimicry produced very different results. 
“These were three-dimensional structures that very 
accurately represented the way human tissue is structured 
in the body,” says Wolf. The bioreactor performed even 
better in space, as was later demonstrated by Wolf himself 
as an astronaut onboard the STS-86 mission to the Mir 
Space Station. 
“When I first put the space-grown tissue samples 
under the microscope, I was astounded. With many years 
of experience culturing tissues, I had never seen any so 
well organized and with such fine structure,” Wolf says. 
It was another breakthrough moment, he says, similar to 
when the team first discovered the ability to assemble 3D 
tissue on Earth using the simulated microgravity of the 
NASA bioreactor. Wolf, Schwarz, and Trinh won NASA 
“Inventor of the Year” honors for their innovation.
Because of gravity, cells grown in Petri dishes settle in flat layers 
rather than assemble into 3D tissues like in the human body. By 
mimicking microgravity, the NASA bioreactor yields healthier, 
more realistic cell cultures.
https://ntrs.nasa.gov/search.jsp?R=20120001891 2019-08-30T19:08:04+00:00Z
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Astronaut David Wolf performs maintenance on a NASA bioreactor unit onboard the Mir space station. Experiments conducted by 
Wolf demonstrated that the bioreactor produces even more effective cell growth results in space. 
partnership 
In 1990, Anderson and Schwarz licensed patents for 
the rotating wall bioreactor technology and founded 
Synthecon Inc. in Houston, Texas, to commercialize the 
device. 
“When they saw what the technology could do, they 
thought, ‘Wow, we really have a better mousetrap,’” 
says Bill Anderson, Charles Anderson’s son and current 
president of the company. Synthecon’s founders saw great 
potential in the bioreactor not only as a powerful tool for 
growing healthy cell cultures, but also as an enabler for 
more effective drug development and production tech-
niques and even entirely new fields of medicine. 
The problem was waiting for the rest of the medical 
industry to catch up, explains Anderson. Scientists were 
satisfied using flasks to culture cells, and drug companies 
were relying on the resulting two-dimensional cells, 
unlike any in the human body, to provide them with data 
for their pharmaceutical compounds.
“The technology was 7 to 8 years ahead of its time,” 
Anderson says. 
While Synthecon worked to demonstrate the potential 
of the rotating wall bioreactor, it received significant sup-
port from NASA.
“We were fortunate in the early days that NASA saw 
the importance of the technology and formed a grant 
program around it,” Anderson says. The Agency funded 
researchers from schools like Harvard University and the 
Massachusetts Institute of Technology to test the device’s 
value for what was then a burgeoning medical field—tis-
sue engineering, seeding an artificial matrix with cells that 
grow into implantable human tissues. Synthecon provided 
the bioreactors for these studies, and the results—success 
growing different tissue types, as well as tumor models 
for testing cancer treatments outside of the body—led to 
numerous published findings that added relevance to the 
technology. 
“It really helped us stay alive when most small busi-
nesses don’t get that benefit,” says Anderson. 
Benefits
Synthecon has since built a portfolio of patents based 
on the original NASA bioreactor and improved upon 
the original technology in a number of ways, creating 
models inexpensive enough to be disposable, as well as 
automated versions that can change the growth media 
without stopping the reactor’s rotation. Now the com-
pany’s NASA-developed Rotary Cell Culture Systems 
(RCCS)—an “R&D 100” award-winning technology—
are key tools for medical research being conducted around 
the globe, and the company, bioreactor technology, and 
original NASA innovators were all inducted into the 
Space Technology Hall of Fame in 2011.
“It might have been ahead of its time, but our technol-
ogy is really filling its shoes quickly,” Anderson says. 
Major pharmaceutical companies, Anderson explains, 
spend significant amounts of money on drug discovery 
and now want to test candidate compounds on RCCS-
Title
Tumor cells grow on microcarrier beads 
within a NASA bioreactor. These cells were 
grown as part of NASA-sponsored breast 
cancer research. For a deeper look at the 
benefits provided by the NASA bioreactor, 
scan this code. 
“We have a very 
powerful set of tools 
to make the next set of 
innovations and 
contributions 
to future medical 
science.”
—David Wolf, astronaut 
and co-inventor of the  
NASA bioreactor
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grown, 3D cells to get a more accurate sense of a potential 
drug’s effects. Synthecon is also scaling up the bioreactor 
technology for the production of recombinant proteins 
and antibodies. (Recombinant proteins are expressed from 
cells containing genetically modified DNA; this is the 
method used to create human insulin and the hepatitis B 
vaccine among other vaccinations and disease treatments. 
Synthecon is working with researchers on recombinant 
protein studies that may yield drugs for diseases like 
rheumatoid arthritis and lupus.) The company has found 
that an RCCS can churn out multifold more product than 
standard systems because it treats cells so gently, meaning 
the cells expressing the proteins do not spend energy on 
repair, a major drain on their productivity. A 100-liter 
RCCS can thus generate the same output as a 1,000-liter 
standard system. 
Another 
developing area 
of medical research in 
which Synthecon’s NASA 
technology promises to be a 
major contributor is regenerative 
medicine. Much has been made in recent years about 
the prospects of stem cells to treat conditions as varied as 
cancer, diabetes, and sickle cell anemia. (In simple terms, 
stem cells are special cells that can transform into other 
cell types, offering the potential to replace damaged or 
malfunctioning cells with healthy ones.) A major obsta-
cle, however, is supply. Synthecon is currently engaged 
in studies using its RCCS devices to multiply stem cells 
from umbilical cord blood—a plentiful source without 
the ethical concerns raised by embryonic stem cells. 
Cord blood transplants have already been demonstrated 
to treat leukemia and other cancers, Anderson says, and 
the RCCS offers the means to efficiently generate the 
amounts of healthy stem cells necessary for medical use. 
Synthecon is also helping improve a therapy 
technique for Type 1 diabetes. In the pancreas, tiny 
clusters called islets of Langerhans—each about the size 
of a period—contain certain cells that generate insulin. 
Previous methods of transplanting healthy donor islets 
into a diabetic’s pancreas involved placing the islets into 
a flask before transplantation, resulting in a roughly 
50 percent or worse survival rate for the donor cells, 
Anderson explains. Researchers working with Synthecon’s 
technology found that placing the cells in the bioreactor 
prior to transplantation significantly improved the health 
of the donor islets, to the point where only one-third as 
many were needed to produce a secure therapeutic dose. 
Synthecon is collaborating with the University of Illinois 
at Chicago Transplant Center to conduct a human 
clinical trial in 2011.
“We think the bioreactor is going to provide a lot 
of benefit to a lot of patients moving forward,” says 
Anderson. “The applications seem to grow every year.” 
“I think it is reasonable to say that the fields of regen-
erative medicine and molecular biology have evolved in 
the interim years to complement this technology,” says 
Wolf, who says he is proud to see a technology conceived 
within the government make a successful transfer to the 
private sector. “We have a very powerful set of tools to 
make the next set of innovations and contributions to 
future medical science.”
Wolf believes that the lunchtime epiphany that led to 
the development of the NASA bioreactor is indicative of 
how true innovation works. 
“Innovation is an inherently messy process,” he says. 
“It’s based on the correct balance of sticking to the origi-
nal plan but also being able to appropriately deviate and 
adapt to new information and discoveries. The future of 
NASA, our country, and world is depending on this pro-
cess for ever more innovations for deep space exploration 
and for improving life on Earth.” v
Rotary Cell Culture System™ and RCCS™ are trademarks of 
Synthecon Inc.
Synthecon Inc. has further advanced the bioreactor 
technology, creating platforms like this perfused culture 
system that allows the cell growth medium to be 
exchanged, sampled, or modified without stopping the 
bioreactor’s rotation and potentially damaging the cells. 
